Outcome of older patients with acute myeloid leukemia in first relapse
To provide data for future drug evaluation, we analyzed the outcome of 393 patients aged 50 years or older (median, 64 years) with AML in first relapse after treatment in recent ALFA trials. Salvage options were retrospectively classified as follows: best supportive care (BSC), low‐dose cytarabine (...
Saved in:
| Published in | American journal of hematology Vol. 88; no. 9; pp. 758 - 764 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.09.2013
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0361-8609 1096-8652 1096-8652 |
| DOI | 10.1002/ajh.23498 |
Cover
| Abstract | To provide data for future drug evaluation, we analyzed the outcome of 393 patients aged 50 years or older (median, 64 years) with AML in first relapse after treatment in recent ALFA trials. Salvage options were retrospectively classified as follows: best supportive care (BSC), low‐dose cytarabine (LDAC), gemtuzumab ozogamicin (GO), intensive chemotherapy (ICT), or ICT combined with GO. Second complete remission (CR2) rate was 31% and median post‐relapse survival was 6.8 months (0, 17, 42.5, 53, and 80% and 3.2, 5.6, 8.9, 9, and 19.8 months in BSC, LDAC, GO, ICT, and ICT + GO subsets, respectively). Age, performance status, WBC, CR1 duration, and favorable AML karyotype, but not other cytogenetic or molecular features, influenced post‐relapse outcome. Multivariate adjustment and propensity score matching showed that intensive salvage (ICT/ICT+GO/GO versus LDAC/BSC) was associated with longer post‐relapse survival, at least in patients with CR1 duration ≥12 months (P = 0.001 and 0.0005, respectively). Of interest, GO appeared to be as effective as standard ICT, and ICT + GO combination more effective than standard ICT. In conclusion, older patients with CR1 duration ≥12 months appeared to benefit from intensive salvage and results observed with GO‐containing salvage suggest that GO combination studies should be actively pursued in this setting. Am. J. Hematol. 88:758–764, 2013. © 2013 Wiley Periodicals, Inc. |
|---|---|
| AbstractList | To provide data for future drug evaluation, we analyzed the outcome of 393 patients aged 50 years or older (median, 64 years) with AML in first relapse after treatment in recent ALFA trials. Salvage options were retrospectively classified as follows: best supportive care (BSC), low‐dose cytarabine (LDAC), gemtuzumab ozogamicin (GO), intensive chemotherapy (ICT), or ICT combined with GO. Second complete remission (CR2) rate was 31% and median post‐relapse survival was 6.8 months (0, 17, 42.5, 53, and 80% and 3.2, 5.6, 8.9, 9, and 19.8 months in BSC, LDAC, GO, ICT, and ICT + GO subsets, respectively). Age, performance status, WBC, CR1 duration, and favorable AML karyotype, but not other cytogenetic or molecular features, influenced post‐relapse outcome. Multivariate adjustment and propensity score matching showed that intensive salvage (ICT/ICT+GO/GO versus LDAC/BSC) was associated with longer post‐relapse survival, at least in patients with CR1 duration ≥12 months (
P
= 0.001 and 0.0005, respectively). Of interest, GO appeared to be as effective as standard ICT, and ICT + GO combination more effective than standard ICT. In conclusion, older patients with CR1 duration ≥12 months appeared to benefit from intensive salvage and results observed with GO‐containing salvage suggest that GO combination studies should be actively pursued in this setting. Am. J. Hematol. 88:758–764, 2013. © 2013 Wiley Periodicals, Inc. To provide data for future drug evaluation, we analyzed the outcome of 393 patients aged 50 years or older (median, 64 years) with AML in first relapse after treatment in recent ALFA trials. Salvage options were retrospectively classified as follows: best supportive care (BSC), low‐dose cytarabine (LDAC), gemtuzumab ozogamicin (GO), intensive chemotherapy (ICT), or ICT combined with GO. Second complete remission (CR2) rate was 31% and median post‐relapse survival was 6.8 months (0, 17, 42.5, 53, and 80% and 3.2, 5.6, 8.9, 9, and 19.8 months in BSC, LDAC, GO, ICT, and ICT + GO subsets, respectively). Age, performance status, WBC, CR1 duration, and favorable AML karyotype, but not other cytogenetic or molecular features, influenced post‐relapse outcome. Multivariate adjustment and propensity score matching showed that intensive salvage (ICT/ICT+GO/GO versus LDAC/BSC) was associated with longer post‐relapse survival, at least in patients with CR1 duration ≥12 months (P = 0.001 and 0.0005, respectively). Of interest, GO appeared to be as effective as standard ICT, and ICT + GO combination more effective than standard ICT. In conclusion, older patients with CR1 duration ≥12 months appeared to benefit from intensive salvage and results observed with GO‐containing salvage suggest that GO combination studies should be actively pursued in this setting. Am. J. Hematol. 88:758–764, 2013. © 2013 Wiley Periodicals, Inc. To provide data for future drug evaluation, we analyzed the outcome of 393 patients aged 50 years or older (median, 64 years) with AML in first relapse after treatment in recent ALFA trials. Salvage options were retrospectively classified as follows: best supportive care (BSC), low-dose cytarabine (LDAC), gemtuzumab ozogamicin (GO), intensive chemotherapy (ICT), or ICT combined with GO. Second complete remission (CR2) rate was 31% and median post-relapse survival was 6.8 months (0, 17, 42.5, 53, and 80% and 3.2, 5.6, 8.9, 9, and 19.8 months in BSC, LDAC, GO, ICT, and ICT+GO subsets, respectively). Age, performance status, WBC, CR1 duration, and favorable AML karyotype, but not other cytogenetic or molecular features, influenced post-relapse outcome. Multivariate adjustment and propensity score matching showed that intensive salvage (ICT/ICT+GO/GO versus LDAC/BSC) was associated with longer post-relapse survival, at least in patients with CR1 duration ≥12 months (P=0.001 and 0.0005, respectively). Of interest, GO appeared to be as effective as standard ICT, and ICT+GO combination more effective than standard ICT. In conclusion, older patients with CR1 duration ≥12 months appeared to benefit from intensive salvage and results observed with GO-containing salvage suggest that GO combination studies should be actively pursued in this setting. Am. J. Hematol. 88:758-764, 2013. © 2013 Wiley Periodicals, Inc. [PUBLICATION ABSTRACT] To provide data for future drug evaluation, we analyzed the outcome of 393 patients aged 50 years or older (median, 64 years) with AML in first relapse after treatment in recent ALFA trials. Salvage options were retrospectively classified as follows: best supportive care (BSC), low-dose cytarabine (LDAC), gemtuzumab ozogamicin (GO), intensive chemotherapy (ICT), or ICT combined with GO. Second complete remission (CR2) rate was 31% and median post-relapse survival was 6.8 months (0, 17, 42.5, 53, and 80% and 3.2, 5.6, 8.9, 9, and 19.8 months in BSC, LDAC, GO, ICT, and ICT + GO subsets, respectively). Age, performance status, WBC, CR1 duration, and favorable AML karyotype, but not other cytogenetic or molecular features, influenced post-relapse outcome. Multivariate adjustment and propensity score matching showed that intensive salvage (ICT/ICT+GO/GO versus LDAC/BSC) was associated with longer post-relapse survival, at least in patients with CR1 duration ≥12 months (P = 0.001 and 0.0005, respectively). Of interest, GO appeared to be as effective as standard ICT, and ICT + GO combination more effective than standard ICT. In conclusion, older patients with CR1 duration ≥12 months appeared to benefit from intensive salvage and results observed with GO-containing salvage suggest that GO combination studies should be actively pursued in this setting. To provide data for future drug evaluation, we analyzed the outcome of 393 patients aged 50 years or older (median, 64 years) with AML in first relapse after treatment in recent ALFA trials. Salvage options were retrospectively classified as follows: best supportive care (BSC), low-dose cytarabine (LDAC), gemtuzumab ozogamicin (GO), intensive chemotherapy (ICT), or ICT combined with GO. Second complete remission (CR2) rate was 31% and median post-relapse survival was 6.8 months (0, 17, 42.5, 53, and 80% and 3.2, 5.6, 8.9, 9, and 19.8 months in BSC, LDAC, GO, ICT, and ICT + GO subsets, respectively). Age, performance status, WBC, CR1 duration, and favorable AML karyotype, but not other cytogenetic or molecular features, influenced post-relapse outcome. Multivariate adjustment and propensity score matching showed that intensive salvage (ICT/ICT+GO/GO versus LDAC/BSC) was associated with longer post-relapse survival, at least in patients with CR1 duration ≥12 months (P = 0.001 and 0.0005, respectively). Of interest, GO appeared to be as effective as standard ICT, and ICT + GO combination more effective than standard ICT. In conclusion, older patients with CR1 duration ≥12 months appeared to benefit from intensive salvage and results observed with GO-containing salvage suggest that GO combination studies should be actively pursued in this setting.To provide data for future drug evaluation, we analyzed the outcome of 393 patients aged 50 years or older (median, 64 years) with AML in first relapse after treatment in recent ALFA trials. Salvage options were retrospectively classified as follows: best supportive care (BSC), low-dose cytarabine (LDAC), gemtuzumab ozogamicin (GO), intensive chemotherapy (ICT), or ICT combined with GO. Second complete remission (CR2) rate was 31% and median post-relapse survival was 6.8 months (0, 17, 42.5, 53, and 80% and 3.2, 5.6, 8.9, 9, and 19.8 months in BSC, LDAC, GO, ICT, and ICT + GO subsets, respectively). Age, performance status, WBC, CR1 duration, and favorable AML karyotype, but not other cytogenetic or molecular features, influenced post-relapse outcome. Multivariate adjustment and propensity score matching showed that intensive salvage (ICT/ICT+GO/GO versus LDAC/BSC) was associated with longer post-relapse survival, at least in patients with CR1 duration ≥12 months (P = 0.001 and 0.0005, respectively). Of interest, GO appeared to be as effective as standard ICT, and ICT + GO combination more effective than standard ICT. In conclusion, older patients with CR1 duration ≥12 months appeared to benefit from intensive salvage and results observed with GO-containing salvage suggest that GO combination studies should be actively pursued in this setting. |
| Author | Turlure, Pascal Micol, Jean‐Baptiste Malfuson, Jean‐Valère Dombret, Hervé Sarkozy, Clémentine Thomas, Xavier Fenaux, Pierre Chevret, Sylvie Merabet, Fathia Celli‐Lebras, Karine Terré, Christine Castaigne, Sylvie Pautas, Cécile Gardin, Claude Preudhomme, Claude Quesnel, Bruno Gachard, Nathalie |
| Author_xml | – sequence: 1 givenname: Clémentine surname: Sarkozy fullname: Sarkozy, Clémentine organization: University Versailles ‐ Saint Quentin – sequence: 2 givenname: Claude surname: Gardin fullname: Gardin, Claude organization: University Paris 13 – sequence: 3 givenname: Nathalie surname: Gachard fullname: Gachard, Nathalie organization: University Limoges – sequence: 4 givenname: Fathia surname: Merabet fullname: Merabet, Fathia organization: University Versailles ‐ Saint Quentin – sequence: 5 givenname: Pascal surname: Turlure fullname: Turlure, Pascal organization: University Limoges – sequence: 6 givenname: Jean‐Valère surname: Malfuson fullname: Malfuson, Jean‐Valère organization: Hôpital d'Instruction des Armées – sequence: 7 givenname: Cécile surname: Pautas fullname: Pautas, Cécile organization: University Paris 12 – sequence: 8 givenname: Jean‐Baptiste surname: Micol fullname: Micol, Jean‐Baptiste organization: University Paris 7 – sequence: 9 givenname: Xavier surname: Thomas fullname: Thomas, Xavier organization: Hôpital Lyon Sud – sequence: 10 givenname: Bruno surname: Quesnel fullname: Quesnel, Bruno organization: University Lille – sequence: 11 givenname: Karine surname: Celli‐Lebras fullname: Celli‐Lebras, Karine organization: University Paris 7 – sequence: 12 givenname: Claude surname: Preudhomme fullname: Preudhomme, Claude organization: University Lille – sequence: 13 givenname: Christine surname: Terré fullname: Terré, Christine organization: University Versailles ‐ Saint Quentin – sequence: 14 givenname: Pierre surname: Fenaux fullname: Fenaux, Pierre organization: University Paris 13 – sequence: 15 givenname: Sylvie surname: Chevret fullname: Chevret, Sylvie organization: University Paris 7 – sequence: 16 givenname: Sylvie surname: Castaigne fullname: Castaigne, Sylvie organization: University Versailles ‐ Saint Quentin – sequence: 17 givenname: Hervé surname: Dombret fullname: Dombret, Hervé organization: University Paris 7 |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23749683$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kctOHDEQRS0EguGxyA9ElrIJiwE_ut32EqHwEhKbZG257Wrhibs9sd0azd_HZIYNCqsqqc69qqp7ig6nOAFCXyi5ooSwa7N6vWK8UfIALShRYilFyw7RgnBBa0_UCTrNeUUIpY0kx-iE8a5RQvIFunuZi40j4DjgGBwkvDbFw1Qy3vjyio2dC-BxCyF6hwPMv2H0BvsJDz7lghMEs85wjo4GEzJc7OsZ-nX34-ftw_L55f7x9uZ5aXnL5bIXorONbfre8YECdQPj1kmQglnrHOFWtKK3TsnOKiflYMHROlOC9Y1lip-h7zvfdYp_ZshFjz5bCMFMEOesacO6eiZXbUW_fUBXcU5T3e6NEg3tVEsr9XVPzf0ITq-TH03a6vcPVeB6B9gUc04waOtLfVGcSjI-aEr0Wwa6ZqD_ZVAVlx8U76b_Y_fuGx9g-zmob54edoq_qIGU8w |
| CitedBy_id | crossref_primary_10_1016_j_jgo_2023_101626 crossref_primary_10_1182_bloodadvances_2018016121 crossref_primary_10_1634_theoncologist_2017_0604 crossref_primary_10_1002_ajh_23653 crossref_primary_10_1002_jha2_600 crossref_primary_10_1007_s12185_022_03483_w crossref_primary_10_2217_fon_2019_0201 crossref_primary_10_1080_17474086_2016_1187063 crossref_primary_10_1002_cam4_3871 crossref_primary_10_1517_21678707_2015_1089168 crossref_primary_10_1002_cncr_29428 crossref_primary_10_1080_10428194_2022_2140288 crossref_primary_10_1038_s41571_023_00813_7 crossref_primary_10_1016_j_yexcr_2018_08_035 crossref_primary_10_1016_j_leukres_2016_05_025 crossref_primary_10_1080_14756366_2018_1490734 crossref_primary_10_1097_MOH_0000000000000490 crossref_primary_10_1016_j_ctrv_2021_102334 crossref_primary_10_1007_s12185_018_2534_z crossref_primary_10_1080_10428194_2020_1864354 crossref_primary_10_1080_10428194_2023_2207698 crossref_primary_10_3390_ijms21010310 crossref_primary_10_1111_bjh_15077 crossref_primary_10_3389_fonc_2023_1204895 crossref_primary_10_3390_molecules26216648 crossref_primary_10_1182_blood_2022016362 crossref_primary_10_1007_s15004_022_9706_y crossref_primary_10_18553_jmcp_2021_27_10_1469 crossref_primary_10_3238_PersOnko_2020_11_20_01 crossref_primary_10_3389_fonc_2018_00152 crossref_primary_10_1182_bloodadvances_2019000197 crossref_primary_10_3109_10428194_2014_986478 crossref_primary_10_3390_jcm4040665 crossref_primary_10_1002_ijc_33595 crossref_primary_10_3390_jcm13020549 crossref_primary_10_1016_j_clml_2018_02_005 crossref_primary_10_1016_j_exphem_2018_05_005 crossref_primary_10_1038_nature22993 crossref_primary_10_1016_j_leukres_2015_05_010 crossref_primary_10_1007_s15015_023_3076_7 crossref_primary_10_1016_j_leukres_2014_11_009 crossref_primary_10_1182_blood_2016_08_733196 crossref_primary_10_1038_s41598_018_33982_y |
| Cites_doi | 10.1200/JCO.2009.23.2652 10.1200/JCO.2011.37.9743 10.3324/haematol.2010.027516 10.3324/haematol.2010.036921 10.2307/2344317 10.1038/leu.2009.214 10.1182/blood-2002-01-0195 10.1182/blood-2007-02-069666 10.1038/sj.leu.2401668 10.1038/sj.leu.2404434 10.1002/cncr.25554 10.1634/theoncologist.2008-0100 10.1182/blood-2009-01-197871 10.1111/j.2517-6161.1972.tb00899.x 10.1007/s00280-002-0546-z 10.1080/01621459.1958.10501452 10.1182/blood-2011-03-340273 10.1200/JCO.2007.15.9764 10.1016/S0140-6736(12)60485-1 10.1002/ajh.22201 10.1016/j.ctrv.2007.09.001 10.1007/s00280-003-0671-3 10.1038/sj.leu.2403243 10.1200/JCO.2012.43.0132 10.1038/leu.2011.25 10.1200/JCO.2003.04.036 10.1200/JCO.2012.42.2964 10.1016/j.leukres.2009.10.001 10.1200/JCO.2005.06.027 10.3324/haematol.2010.034074 |
| ContentType | Journal Article |
| Copyright | Copyright © 2013 Wiley Periodicals, Inc. |
| Copyright_xml | – notice: Copyright © 2013 Wiley Periodicals, Inc. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. 7X8 |
| DOI | 10.1002/ajh.23498 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef ProQuest Health & Medical Complete (Alumni) MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1096-8652 |
| EndPage | 764 |
| ExternalDocumentID | 3049768161 23749683 10_1002_ajh_23498 AJH23498 |
| Genre | article Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Assistance Publique‐Hôpitaux de Paris (AP‐HP) – fundername: French Programme Hospitalier de Recherche Clinique, French Ministry of Health (AP‐HP IDs, P970901 and P970509) funderid: NCT00931138 and NCT00363025 |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 23M 24P 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDPE ABEML ABIJN ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EGARE EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IH2 IX1 J0M J5H JPC KBYEO KD1 KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6P MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D P6G PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWI RX1 RYL SAMSI SUPJJ TEORI TR2 UB1 V2E V8K VH1 W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR X7M XG1 XPP XV2 ZGI ZXP ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM AAMMB AEFGJ AGXDD AIDQK AIDYY K9. 7X8 |
| ID | FETCH-LOGICAL-c3538-b667c4c4bbd3f1e1df23cd8e862ccdd03c656bcd987c9d88fced162c962b4c293 |
| IEDL.DBID | DR2 |
| ISSN | 0361-8609 1096-8652 |
| IngestDate | Fri Jul 11 08:19:20 EDT 2025 Sat Jul 05 16:41:15 EDT 2025 Wed Feb 19 01:54:24 EST 2025 Thu Apr 24 23:12:25 EDT 2025 Tue Jul 01 02:27:51 EDT 2025 Wed Jan 22 16:26:55 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor Copyright © 2013 Wiley Periodicals, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3538-b667c4c4bbd3f1e1df23cd8e862ccdd03c656bcd987c9d88fced162c962b4c293 |
| Notes | Conflict of interest: Nothing to report C.S. and C.G. contributed equally to this work. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| PMID | 23749683 |
| PQID | 1426417951 |
| PQPubID | 866345 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_1427001395 proquest_journals_1426417951 pubmed_primary_23749683 crossref_citationtrail_10_1002_ajh_23498 crossref_primary_10_1002_ajh_23498 wiley_primary_10_1002_ajh_23498_AJH23498 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | September 2013 2013-09-00 2013-Sep 20130901 |
| PublicationDateYYYYMMDD | 2013-09-01 |
| PublicationDate_xml | – month: 09 year: 2013 text: September 2013 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: New York |
| PublicationTitle | American journal of hematology |
| PublicationTitleAlternate | Am J Hematol |
| PublicationYear | 2013 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2010; 34 2010; 11 2011; 117 1958; 53 2011; 96 2008; 34 2008; 13 2003; 18 1991 1972; 135 2007; 109 2003; 51 2003; 52 2009; 114 2012; 10 2005; 23 2001; 86 2012; 30 2010; 24 2000; 14 2010; 28 2002; 89 2002; 100 2008; 26 2011; 25 2007; 21 2012; 379 1972; 34 2012; 87 2010; 95 2003; 21 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_13_1 e_1_2_7_12_1 e_1_2_7_11_1 e_1_2_7_10_1 ISCN (International System for Human Cytoge‐ netic Nomenclature) (e_1_2_7_14_1) 1991 e_1_2_7_26_1 e_1_2_7_27_1 e_1_2_7_28_1 e_1_2_7_29_1 Guo S (e_1_2_7_19_1) 2010 e_1_2_7_30_1 Thomas X (e_1_2_7_23_1) 2002; 89 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_33_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_21_1 e_1_2_7_35_1 e_1_2_7_20_1 Ferrara F (e_1_2_7_3_1) 2001; 86 Cox D (e_1_2_7_18_1) 1972; 34 |
| References_xml | – volume: 24 start-page: 467 year: 2010 end-page: 469 article-title: Influence of NPM1 and FLT3‐ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin publication-title: Leukemia – volume: 34 start-page: 752 year: 2010 end-page: 756 article-title: Outcome of patients with FLT3‐mutated acute myeloid leukemia in first relapse publication-title: Leuk Res. – volume: 117 start-page: 974 year: 2011 end-page: 981 article-title: Improved outcome of patients with low‐and intermediate‐risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: Results of a retrospective comparative study publication-title: Cancer – volume: 114 start-page: 3024 year: 2009 end-page: 3032 article-title: AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features publication-title: Blood – volume: 26 start-page: 5192 year: 2008 end-page: 5197 article-title: Long‐term disease‐free survival after gemtuzumab, intermediate‐dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia publication-title: J Clin Oncol – volume: 25 start-page: 939 year: 2011 end-page: 944 article-title: A new leukemia prognostic scoring system for refractory/relapsed adult acute myelogeneous leukaemia patients: A GOELAMS study publication-title: Leukemia – volume: 96 start-page: 837 year: 2011 end-page: 844 article-title: Impact of post‐remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: A comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria publication-title: Haematologica – start-page: 1 year: 1991 end-page: 53 – volume: 53 start-page: 457 year: 1958 end-page: 481 article-title: Non‐parametric estimations from incomplete observations publication-title: JASA – volume: 96 start-page: 681 year: 2011 end-page: 686 article-title: FLT3‐internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype publication-title: Haematologica – volume: 95 start-page: 1857 year: 2010 end-page: 1864 article-title: Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse publication-title: Haematologica – volume: 28 start-page: 808 year: 2010 end-page: 814 article-title: Randomized study of intensified anthracycline doses for induction and recombinant interleukin‐2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: Results of the ALFA‐9801 study publication-title: J Clin Oncol – volume: 23 start-page: 1969 year: 2005 end-page: 1978 article-title: Prognostic index for adult patients with acute myeloid leukemia in first relapse publication-title: J Clin Oncol – volume: 135 start-page: 185 year: 1972 end-page: 206 article-title: Asymptotically efficient rank invariant test procedures publication-title: JR Stat Soc A – volume: 10 start-page: 3921 year: 2012 end-page: 3923 article-title: Gemtuzumab ozogamicin: Time to resurrect? publication-title: J Clin Oncol – volume: 109 start-page: 5129 year: 2007 end-page: 5135 article-title: Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial publication-title: Blood – volume: 34 start-page: 49 year: 2008 end-page: 60 article-title: Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia publication-title: Cancer Treat Rev – volume: 18 start-page: 293 year: 2003 end-page: 302 article-title: Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse publication-title: Leukemia – volume: 52 start-page: 449 year: 2003 end-page: 452 article-title: Mylotarg, fludarabine, cytarabine (ara‐C), and cyclosporine (MFAC) regimen as post‐remission therapy in acute myelogenous leukemia publication-title: Cancer Chemother Pharmacol – volume: 117 start-page: 6987 year: 2011 end-page: 6990 article-title: FLT3/ITD AML and the law of unintended consequences publication-title: Blood – volume: 87 start-page: 62 year: 2012 end-page: 65 article-title: Fractionned doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50–70 years old: A phase 1/2 study of the Acute Leukemia French Association (ALFA) publication-title: Am J Hematol – volume: 34 start-page: 187 year: 1972 end-page: 220 article-title: Regression models and life tables publication-title: JR Stat Soc B – volume: 51 start-page: 87 year: 2003 end-page: 90 article-title: Pilot study of mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia publication-title: Cancer Chemother Pharmacol – volume: 14 start-page: 226 year: 2000 end-page: 231 article-title: Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high‐dose cytosine arabinoside and mitoxantrone (S‐HAM) salvage therapy: Relevance of cytogenetic abnormalities publication-title: Leukemia – volume: 21 start-page: 66 year: 2007 end-page: 71 article-title: High efficacy and safety profile of fractionated doses of mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: A prospective study of the ALFA group publication-title: Leukemia – volume: 379 start-page: 1508 year: 2012 end-page: 1516 article-title: Effect of gemtuzumab ozogamicin on survival of adult patients with de‐novo acute myeloid leukaemia (ALFA‐0701): A randomized, open‐label, phase 3 study publication-title: Lancet – volume: 13 start-page: 1097 year: 2008 end-page: 1108 article-title: Current and emerging strategies for the management of acute myeloid leukemia in the elderly publication-title: Oncologist – volume: 30 start-page: 3924 year: 2012 end-page: 3931 article-title: Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia publication-title: J Clin Oncol – volume: 11 start-page: 91320 year: 2010 – volume: 100 start-page: 2387 year: 2002 end-page: 2392 article-title: Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse publication-title: Blood – volume: 21 start-page: 4642 year: 2003 end-page: 4649 article-title: Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia publication-title: J Clin Oncol – volume: 30 start-page: 2492 year: 2012 end-page: 2499 article-title: Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: Results from the CLASSIC I Trial publication-title: J Clin Oncol – volume: 86 start-page: 814 year: 2001 end-page: 820 article-title: Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission publication-title: Haematologica – volume: 89 start-page: 795 year: 2002 end-page: 807 article-title: Treatment of acute myeloid leukemias in the adult in relapse publication-title: Bull Cancer – ident: e_1_2_7_10_1 doi: 10.1200/JCO.2009.23.2652 – ident: e_1_2_7_28_1 doi: 10.1200/JCO.2011.37.9743 – ident: e_1_2_7_6_1 doi: 10.3324/haematol.2010.027516 – ident: e_1_2_7_11_1 doi: 10.3324/haematol.2010.036921 – ident: e_1_2_7_17_1 doi: 10.2307/2344317 – ident: e_1_2_7_27_1 doi: 10.1038/leu.2009.214 – ident: e_1_2_7_25_1 doi: 10.1182/blood-2002-01-0195 – ident: e_1_2_7_12_1 doi: 10.1182/blood-2007-02-069666 – ident: e_1_2_7_2_1 doi: 10.1038/sj.leu.2401668 – ident: e_1_2_7_20_1 doi: 10.1038/sj.leu.2404434 – volume: 86 start-page: 814 year: 2001 ident: e_1_2_7_3_1 article-title: Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission publication-title: Haematologica – ident: e_1_2_7_24_1 doi: 10.1002/cncr.25554 – ident: e_1_2_7_34_1 doi: 10.1634/theoncologist.2008-0100 – ident: e_1_2_7_15_1 doi: 10.1182/blood-2009-01-197871 – volume: 34 start-page: 187 year: 1972 ident: e_1_2_7_18_1 article-title: Regression models and life tables publication-title: JR Stat Soc B doi: 10.1111/j.2517-6161.1972.tb00899.x – ident: e_1_2_7_33_1 doi: 10.1007/s00280-002-0546-z – ident: e_1_2_7_16_1 doi: 10.1080/01621459.1958.10501452 – ident: e_1_2_7_26_1 doi: 10.1182/blood-2011-03-340273 – ident: e_1_2_7_22_1 doi: 10.1200/JCO.2007.15.9764 – ident: e_1_2_7_30_1 doi: 10.1016/S0140-6736(12)60485-1 – ident: e_1_2_7_21_1 doi: 10.1002/ajh.22201 – ident: e_1_2_7_35_1 doi: 10.1016/j.ctrv.2007.09.001 – ident: e_1_2_7_32_1 doi: 10.1007/s00280-003-0671-3 – ident: e_1_2_7_4_1 doi: 10.1038/sj.leu.2403243 – ident: e_1_2_7_29_1 doi: 10.1200/JCO.2012.43.0132 – ident: e_1_2_7_9_1 doi: 10.1038/leu.2011.25 – ident: e_1_2_7_13_1 doi: 10.1200/JCO.2003.04.036 – ident: e_1_2_7_31_1 doi: 10.1200/JCO.2012.42.2964 – start-page: 1 volume-title: Supplement to an International System for Human Cytogenetic Nomenclature year: 1991 ident: e_1_2_7_14_1 – start-page: 91320 volume-title: SAGE Publications, Inc year: 2010 ident: e_1_2_7_19_1 – volume: 89 start-page: 795 year: 2002 ident: e_1_2_7_23_1 article-title: Treatment of acute myeloid leukemias in the adult in relapse publication-title: Bull Cancer – ident: e_1_2_7_7_1 doi: 10.1016/j.leukres.2009.10.001 – ident: e_1_2_7_5_1 doi: 10.1200/JCO.2005.06.027 – ident: e_1_2_7_8_1 doi: 10.3324/haematol.2010.034074 |
| SSID | ssj0011480 |
| Score | 2.2524562 |
| Snippet | To provide data for future drug evaluation, we analyzed the outcome of 393 patients aged 50 years or older (median, 64 years) with AML in first relapse after... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 758 |
| SubjectTerms | Age Factors Aged Aminoglycosides - administration & dosage Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cytarabine - administration & dosage Female Hematology Humans Karyotyping Leukemia, Myeloid, Acute - mortality Leukemia, Myeloid, Acute - therapy Male Medical research Medical treatment Middle Aged Recurrence Remission Induction - methods Salvage Therapy - methods Survival Analysis Treatment Outcome |
| Title | Outcome of older patients with acute myeloid leukemia in first relapse |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fajh.23498 https://www.ncbi.nlm.nih.gov/pubmed/23749683 https://www.proquest.com/docview/1426417951 https://www.proquest.com/docview/1427001395 |
| Volume | 88 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VPSAuPFoeC6UyCCEu2Sax4yTitKJdLUUFCVGpB6TIGdvq0t2kYpND-fWMnQdqKRLiFsmT2LFn7G9szzcAr9Mkt0LyNMCIfBMhNJlUpnWgpUKlkXRIuWjkk09ycSqOz5KzLXg3xMJ0_BDjhpuzDD9fOwNX5ebgN2mo-n4-jbnIXaBvxKXjzT_8MlJHOZgfdueUUZDJMB9YhcL4YHzz-lr0B8C8jlf9gjO_D9-Gpnb3TC6mbVNO8ecNFsf__JcHcK8HomzWac5D2DLVDuzOKnLC11fsDfNXQ_2e-w7cOelP4Hdh_rlt6OuG1ZbVLsM365lZN8xt6TKFbWPY-sqs6qVmK9NemPVSsWXF7JKAJnOxM5cb8whO50df3y-CPhdDgNzNiaWUKQoUZam5jUykbcxRZ4YcIkStQ44EDEvUeZZirrPMotERleUyLgUSpngM21VdmafAQp7YTNuQXDUreFjmMrGYqChUqU21ERN4O4xKgT1RucuXsSo6iuW4oO4qfHdN4NUoetmxc9wmtDcMbdEb6IY8HkKCNBkl0QRejsVkWu68RFWmbr1M6iFyMoEnnUqMtcQ8FbnMODXWD-zfqy9mxwv_8OzfRZ_D3din3XB32fZgu_nRmhcEfppyn7T8w8d9r-u_ABc3ADE |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgEXCi2FpQUMQohLtknsOI7EZVWxWkq3SKiVekGR44dYuptUbHIov56x80AtICFukTyJHXvG_sZjfwPwOk0yyzhNAxWhb8KYRpMSWgeaSyW1Qh2S7jby_ITPztjReXK-Ae_6uzAtP8Sw4eYsw8_XzsDdhvTBL9ZQ-e3rOKYsE7fgto_POUj0eSCPckA_bCOVUSB4mPW8QmF8MLx6fTX6DWJeR6x-yZluwZe-se1Jk4txUxdj9eMGj-P__s0DuN9hUTJplechbJhyG3YmJfrhqyvyhvjToX7bfRvuzLsg_A5MPzU1ft6QypLKJfkmHTnrmrhdXSJVUxuyujLLaqHJ0jQXZrWQZFESu0CsSdz1mcu1eQRn0_enh7OgS8cQKOqmxYLzVDHFikJTG5lI25gqLQz6REppHVKF2LBQOhOpyrQQVhkdYVnG44IphBW7sFlWpXkCJKSJFdqG6K1ZRsMi44lViYxCmdpUGzaCt_2w5KrjKncpM5Z5y7Ic59hdue-uEbwaRC9bgo4_Ce33Y5t3NrpGpwfBIM5HSTSCl0MxWpcLmcjSVI2XST1KTkbwuNWJoZaYpizjgmJj_cj-vfp8cjTzD0__XfQF3J2dzo_z4w8nH_fgXuyzcLijbfuwWX9vzDPEQnXx3Kv8Tw08A1Y |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlVceLRQFlowCCEu2Sax4zjitCqslkILQlTqASly_BBLd5MVmxzaX9-x80DlISFukTyJHXvG_mZsfwPwIk0yyzhNAxWhb8KYRpMSWgeaSyW1Qh2S7jby8QmfnbKjs-RsA173d2Fafogh4OYsw8_XzsBX2h78JA2V37-NY8oycQNuMo7LpENEnwfuKIfzw3ajMgoED7OeViiMD4ZXry9GvyHM64DVrzjTO_C1b2t70OR83NTFWF3-QuP4nz9zF253SJRMWtW5Bxum3IadSYle-PKCvCT-bKgPum_D1nG3Bb8D049NjV83pLKkcim-SUfNuiYupkukampDlhdmUc01WZjm3CznksxLYueINIm7PLNam_twOn375XAWdMkYAkXdpFhwniqmWFFoaiMTaRtTpYVBj0gprUOqEBkWSmciVZkWwiqjIyzLeFwwhaDiAWyWVWkeAglpYoW2IfpqltGwyHhiVSKjUKY21YaN4FU_KrnqmMpdwoxF3nIsxzl2V-67awTPB9FVS8_xJ6G9fmjzzkLX6PIgFMTZKIlG8GwoRttyGyayNFXjZVKPkZMR7LYqMdQS05RlXFBsrB_Yv1efT45m_uHRv4s-ha1Pb6b5h3cn7x_Drdin4HDn2vZgs_7RmH0EQnXxxCv8FQQAAgU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Outcome+of+older+patients+with+acute+myeloid+leukemia+in+first+relapse&rft.jtitle=American+journal+of+hematology&rft.au=Sarkozy%2C+Cl%C3%A9mentine&rft.au=Gardin%2C+Claude&rft.au=Gachard%2C+Nathalie&rft.au=Merabet%2C+Fathia&rft.date=2013-09-01&rft.issn=0361-8609&rft.eissn=1096-8652&rft.volume=88&rft.issue=9&rft.spage=758&rft.epage=764&rft_id=info:doi/10.1002%2Fajh.23498&rft.externalDBID=10.1002%252Fajh.23498&rft.externalDocID=AJH23498 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0361-8609&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0361-8609&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0361-8609&client=summon |